Cleveland-Cliffs Buy Call Rests on Aggressive 2027 Margin Goals, But Cash Flow Proof Still Missing
Read source articleWhat happened
A Seeking Alpha article rates Cleveland-Cliffs a Buy, arguing that sales policy reforms—indexed pricing, lower discounts, and cost pass-throughs—plus high steel prices and tariffs could drive 2027 EBITDA above $4 billion, well ahead of the $2.54 billion consensus. The article highlights the expiration of an unprofitable slab contract, which frees capacity and improves mix, and points to fourth-quarter 2026 margins as the first hard test of these reforms. However, the latest DeepValue master report maintains a WAIT rating, emphasizing that Q1 2026 free cash flow was negative $477 million, cash is only $45 million against $7.76 billion of long-term debt, and the turnaround still requires proof of cash conversion. The reforms cited are not new to the thesis; the master report already incorporated the slab exit and contract improvements into its bull scenario (25% probability, $13.50 value), but the headline EBITDA target is far above consensus and as yet unsupported by quarterly data. Consequently, the news does not change the fundamental risk-reward: the stock remains a show-me story until Q4 margins and Q3 cash flow demonstrate the reforms are working.
Implication
The gap between management's >$4 billion EBITDA target and consensus $2.54 billion is enormous and requires both sustained steel pricing and successful contract reform execution; failure to bridge this gap would likely disappoint the market. Watch the Q4 2026 earnings release for evidence that indexed pricing and cost pass-throughs are actually lifting realized margins per ton, not just revenue. Also monitor free cash flow and revolver borrowings; any further deterioration would undermine the liquidity bridge and increase refinancing risk. If Q4 margins show clear improvement and management reiterates or raises 2027 guidance, the probability of the bull scenario may rise, but until then the base case probability of 45% at $10.50 value remains appropriate. Above $12.50, the risk-reward skews negative, and below $8.50, the asymmetric return improves, consistent with the master report's trim and entry levels.
Thesis delta
No material shift in our WAIT rating. The news article articulates the bull case already embedded in our scenarios, but the $4 billion EBITDA target is aggressive and unproven. We would need to see Q4 margin evidence or positive free cash flow before upgrading probabilities.
Confidence
Moderate-High